Jennison Associates
LENZ

Jennison Associates’s LENZ Therapeutics LENZ Stock Holding History

Jennison Associates’s Portfolio LENZ Stock Details LENZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-134,740
Closed -$3.01M – 613
2024
Q1 		$3.01M Buy
+134,740
New +$2.8M ﹤0.01% 448
2021
Q4 		– Sell
-42,339
Closed -$4.86M – 736
2021
Q3 		$4.86M Sell
42,339
-518
-1% -$76.7K ﹤0.01% 486
2021
Q2 		$9.22M Buy
+42,857
New +$7.46M 0.01% 468

Other funds holding LENZ

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
AWG
Alpha Wave Global New York $791M AUM 113.77% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
SAM
Sectoral Asset Management Montreal, Quebec, Canada $121M AUM 73.47% 1-Year Est. Return
7IH
72 Investment Holdings Stamford, Connecticut $49.6M AUM 684.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Jennison Associates's LENZ Position: Q2 2024 in Review

Jennison Associates sold out of LENZ Therapeutics (LENZ) in Q2 2024, closing a stake of 134,740 shares — an estimated $3.01M sold.

Jennison Associates first reported a position in LENZ in Q2 2021 and held it in 3 quarters. The position peaked at $9.22M in Q2 2021. 65 funds tracked by Wall St. Rank hold LENZ as of Q2 2024.

  • Jennison Associates reported no remaining LENZ Therapeutics position as of Q2 2024 after selling out during the quarter.
  • Jennison Associates sold 134,740 LENZ Therapeutics shares in Q2 2024, an estimated $3.01M.
  • Jennison Associates first reported a position in LENZ Therapeutics in Q2 2021 and held it in 3 quarters.
  • Jennison Associates's LENZ Therapeutics position peaked at $9.22M in Q2 2021.
  • 65 funds tracked by Wall St. Rank held LENZ Therapeutics as of Q2 2024.

Based on Jennison Associates's 13F filing for Q2 2024, filed 5 Aug 2024.